Abstract 1674P
Background
Nasopharyngeal carcinoma (NPC) can have implications on the sexual health of patients suffering from this cancer. This can be affected by various factors, whether it be the cancer itself, the treatments administered, or the associated psychological stress. However, sexual disorders are often overlooked in the management of these patients. The aim: is to assess the sexual health of patients with NPC at different stages of their treatment.
Methods
This is a descriptive analytical study evaluating sexual health in adult patients with NPC using EORTC SHQ-C22 Questionnaire. Thirty married patients were included between September and December 2023. The mean age was 45 years [32-68] with a sex ratio of 4 (24/6). Tumor stage (III) was the most represented (25 patients; 83.3%). The questionnaire was translated into colloquial Arabic and administered during treatment for 27 patients (71.4%), and within the first 6 months of follow-up for 3 patients. All patients resided at home with their spouses at the time of the questionnaire.
Results
According to the EORTC SHQ-C22 scale, 17 patients were not sexually active (not at all or a little) during treatment (56.6%) with a feeling of sexual satisfaction (often or quite often) in 17 patients (70.8%). Thirteen patients (43.3%) considered sexual activity to be enjoyable (often or quite often). A negative impact of fatigue and treatment on sexual activity was experienced by 14 patients (46.6%, often or quite often) and a feeling of inability to satisfy their partner was felt by 12 patients (7% a little, 10% often, and 73% quite often). Sexual activity was not painful for 26 patients (86.6%), and concerns about pain during sexual intercourse or intimate physical contact were not felt by 21 patients (70%). Discussion with a doctor about sexuality was absent in most cases (27 patients, 90%). Communication with the partner about sexuality was unsatisfactory in all patients (90% did not communicate and 10% communicated very little). The median score of the EORTC SHQ-C22 was 67 [30-75]. Among these patients, 7 patients (23.3%) wished to receive treatment for their sexuality, and no patient was using any specific sexual treatment.
Conclusions
The search for sexual disorders in patients with NPC is essential, for better quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut National d'Oncologie Rabat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11